Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 168 articles:
HTML format
Text format



Single Articles


    July 2017
  1. AGGOUNE D, Sorel N, Bonnet ML, Goujon JM, et al
    Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
    Leuk Res. 2017;60:94-102.
    PubMed     Text format     Abstract available


  2. MPAKOU VE, Ioannidou HD, Konsta E, Vikentiou M, et al
    Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia.
    Leuk Res. 2017;60:74-81.
    PubMed     Text format     Abstract available


  3. BENICIO MTL, Ribeiro AFT, Americo AD, Furtado FM, et al
    Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
    Leuk Res. 2017;60:109-114.
    PubMed     Text format     Abstract available


    June 2017
  4. BLUM S, Martins F, Lubbert M
    Immunotherapy in adult acute leukemia.
    Leuk Res. 2017;60:63-73.
    PubMed     Text format     Abstract available


  5. ALABDULWAHAB AS, Elsayed HG, Sherisher MA, Zeeneldin A, et al
    The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Leuk Res. 2017;60:58-62.
    PubMed     Text format     Abstract available


  6. KIM T, Tyndel MS, Zhang Z, Ahn J, et al
    Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
    Leuk Res. 2017;59:142-148.
    PubMed     Text format     Abstract available


  7. CHEN L, Guo P, Zhang Y, Li X, et al
    Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
    Leuk Res. 2017;60:44-52.
    PubMed     Text format     Abstract available


  8. HUANG M, Miyake K, Kagami K, Abe M, et al
    Lack of association between deletion polymorphism of BIM gene and in vitro drug sensitivity in B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2017;60:24-30.
    PubMed     Text format     Abstract available


  9. JAIN P, Wang S, Patel KP, Sarwari N, et al
    Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.
    Leuk Res. 2017;59:105-109.
    PubMed     Text format     Abstract available


  10. VAZQUEZ-REYES A, Bobadilla-Morales L, Barba-Barba C, Macias-Salcedo G, et al
    Aneuploidy identification in pre-B acute lymphoblastic leukemia patients at diagnosis by Multiplex Ligation-dependent Probe Amplification (MLPA).
    Leuk Res. 2017;59:117-123.
    PubMed     Text format     Abstract available


  11. CHEN H, Liu KY, Xu LP, Chen YH, et al
    Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
    Leuk Res. 2017;59:136-141.
    PubMed     Text format     Abstract available


    May 2017
  12. ISHDORJ G, Kost SEF, Beiggi S, Zang Y, et al
    A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia.
    Leuk Res. 2017;59:66-74.
    PubMed     Text format     Abstract available


  13. YANG H, Fang Z, Wei Y, Bohannan ZS, et al
    Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia.
    Leuk Res. 2017;59:85-92.
    PubMed     Text format     Abstract available


  14. YAP E, Norziha ZA, Simbun A, Tumian NR, et al
    MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Leuk Res. 2017;59:32-40.
    PubMed     Text format     Abstract available


  15. GU B, Wu X, Chen G, Ma X, et al
    Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2017;59:41-46.
    PubMed     Text format     Abstract available


  16. DUAN MH, Li H, Cai H
    A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Leuk Res. 2017;59:8-11.
    PubMed     Text format     Abstract available


  17. TAN J, Wang Y, Yu SJ, Ma YY, et al
    Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
    Leuk Res. 2017;59:1-7.
    PubMed     Text format     Abstract available


  18. STRICKLAND SA, Sun Z, Ketterling RP, Cherry AM, et al
    Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
    Leuk Res. 2017;59:55-64.
    PubMed     Text format     Abstract available


  19. KUMAR B, Kalvala A, Chu S, Rosen S, et al
    Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
    Leuk Res. 2017;59:124-135.
    PubMed     Text format     Abstract available


  20. GOPALAKRISHNAPILLAI A, Kolb EA, McCahan SM, Barwe SP, et al
    Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Leuk Res. 2017;58:91-97.
    PubMed     Text format     Abstract available


  21. LYONS RM, Marek BJ, Paley C, Esposito J, et al
    Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
    Leuk Res. 2017;56:88-95.
    PubMed     Text format     Abstract available


  22. PATEL S, Mason CC, Glenn MJ, Paxton CN, et al
    Genomic analysis of adult B-ALL identifies potential markers of shorter survival.
    Leuk Res. 2017;56:44-51.
    PubMed     Text format     Abstract available


    April 2017
  23. MEDINGER M, Zeiter D, Heim D, Halter J, et al
    Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Leuk Res. 2017;58:43-47.
    PubMed     Text format     Abstract available


  24. JASTANIAH W, Alsultan A, Al Daama S, Ballourah W, et al
    Treatment results in children with myeloid leukemia of Down syndrome in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Leuk Res. 2017;58:48-54.
    PubMed     Text format     Abstract available


  25. TIRIBELLI M, Raspadori D, Geromin A, Cavallin M, et al
    High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Leuk Res. 2017;58:31-38.
    PubMed     Text format     Abstract available


  26. YANG Y, Ding L, Guo ZK, Zheng XL, et al
    The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells.
    Leuk Res. 2017;55:91-96.
    PubMed     Text format     Abstract available


  27. PASIC I, Lipton JH
    Current approach to the treatment of chronic myeloid leukaemia.
    Leuk Res. 2017;55:65-78.
    PubMed     Text format     Abstract available


  28. ANNEREAU M, Willekens C, El Halabi L, Chahine C, et al
    Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
    Leuk Res. 2017;55:58-64.
    PubMed     Text format     Abstract available


  29. CHIEN WW, Niogret C, Juge R, Lionnard L, et al
    Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
    Leuk Res. 2017;55:41-48.
    PubMed     Text format     Abstract available


  30. GUR HD, Wang SA, Tang Z, Hu S, et al
    Clinical significance of isolated del(7p) in myeloid neoplasms.
    Leuk Res. 2017;55:18-22.
    PubMed     Text format     Abstract available


    March 2017
  31. LI Y, Liu X, Guo X, Liu X, et al
    DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
    Leuk Res. 2017;58:9-13.
    PubMed     Text format     Abstract available


  32. BILOUS N, Abramenko I, Saenko V, Chumak A, et al
    Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Leuk Res. 2017;58:1-8.
    PubMed     Text format     Abstract available


  33. GARCIA C, Rosen A, Kimby E, Aguilar-Santelises M, et al
    Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].
    Leuk Res. 2017 Mar 14. pii: S0145-2126(17)30041.
    PubMed     Text format    


  34. GRANADOS-RIVERON JT, Aquino-Jarquin G
    Reversal of multidrug resistance of leukemia cells is not necessarily induced by direct miR-138/MDR1 promoter interaction.
    Leuk Res. 2017;57:55-56.
    PubMed     Text format    


    February 2017
  35. MAURO FR, Morabito F, Vincelli ID, Petrucci L, et al
    Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.
    Leuk Res. 2017;57:65-71.
    PubMed     Text format     Abstract available


  36. YAN T, Leng Y, Yang X, Gong Y, et al
    High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
    Leuk Res. 2017;57:9-19.
    PubMed     Text format     Abstract available


  37. HU Y, Dong X, Chu G, Lai G, et al
    miR-137 downregulates c-kit expression in acute myeloid leukemia.
    Leuk Res. 2017;57:72-77.
    PubMed     Text format     Abstract available


  38. KANG KW, Kim DS, Lee SR, Sung HJ, et al
    Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
    Leuk Res. 2017;57:1-8.
    PubMed     Text format     Abstract available


  39. PULTE D, Castro FA, Brenner H, Jansen L, et al
    Outcome disparities by insurance type for patients with acute myeloblastic leukemia.
    Leuk Res. 2017;56:75-81.
    PubMed     Text format     Abstract available


  40. GORDON MJ, Tardi P, Loriaux MM, Spurgeon SE, et al
    CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Leuk Res. 2017;53:39-49.
    PubMed     Text format     Abstract available


    January 2017
  41. QUAGLIANO A, Gopalakrishnapillai A, Barwe SP
    Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
    Leuk Res. 2017;56:36-43.
    PubMed     Text format     Abstract available


  42. YAO J, Zhang G, Liang C, Li G, et al
    Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Leuk Res. 2017;55:97-104.
    PubMed     Text format     Abstract available


  43. PATEL JL, Schumacher JA, Frizzell K, Sorrells S, et al
    Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Leuk Res. 2017;56:7-12.
    PubMed     Text format     Abstract available


  44. MOHAMED AM, Balsat M, Koering C, Maucort-Boulch D, et al
    TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
    Leuk Res. 2017;56:21-28.
    PubMed     Text format     Abstract available


  45. HUANG SJ, Lee LJ, Gerrie AS, Gillan TL, et al
    Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.
    Leuk Res. 2017;55:79-90.
    PubMed     Text format     Abstract available


  46. PORTICH JP, Dos Santos RP, Kersting N, Jorge KB, et al
    DNA damage response in patients with pediatric Acute Lymphoid Leukemia during induction therapy.
    Leuk Res. 2017;54:59-65.
    PubMed     Text format     Abstract available


  47. HATTORI A, McSkimming D, Kannan N, Ito T, et al
    RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.
    Leuk Res. 2017;54:47-54.
    PubMed     Text format     Abstract available


  48. JEVTOVIC-STOIMENOV T, Cvetkovic T, Despotovic M, Basic J, et al
    The influence of TNF alpha -308 G/A polymorphism on oxidative stress in patients with chronic lymphocytic leukemia.
    Leuk Res. 2017;54:66-72.
    PubMed     Text format     Abstract available


  49. WANG L, Raffoux E, Thomas X, Yakoub-Agha I, et al
    Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.
    Leuk Res. 2017;54:12-16.
    PubMed     Text format     Abstract available


  50. IRIYAMA N, Tokuhira M, Takaku T, Sato E, et al
    Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
    Leuk Res. 2017;54:55-58.
    PubMed     Text format     Abstract available


  51. CAO S, Lu X, Wang L, Qian X, et al
    The functional polymorphisms of LIS1 are associated with acute myeloid leukemia risk in a Han Chinese population.
    Leuk Res. 2017;54:7-11.
    PubMed     Text format     Abstract available


    December 2016
  52. MARTINELLI S, Maffei R, Fiorcari S, Quadrelli C, et al
    The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli.
    Leuk Res. 2016;54:17-24.
    PubMed     Text format     Abstract available


  53. GRONROOS T, Teppo S, Mehtonen J, Laukkanen S, et al
    Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia.
    Leuk Res. 2016;54:1-6.
    PubMed     Text format     Abstract available


  54. LIU C, Zhao L, Zhao J, Xu Q, et al
    Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
    Leuk Res. 2016;53:57-64.
    PubMed     Text format     Abstract available


  55. LAZZAROTTO D, Candoni A, Fili C, Forghieri F, et al
    Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
    Leuk Res. 2016;53:74-81.
    PubMed     Text format     Abstract available


  56. HEINI AD, Berger MD, Seipel K, Taleghani BM, et al
    Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
    Leuk Res. 2016;53:28-34.
    PubMed     Text format     Abstract available


  57. HUANG L, Wang SA, DiNardo C, Li S, et al
    Tetraploidy/near-tetraploidy acute myeloid leukemia.
    Leuk Res. 2016;53:20-27.
    PubMed     Text format     Abstract available


    November 2016
  58. KONTOS CK, Papageorgiou SG, Diamantopoulos MA, Scorilas A, et al
    mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia.
    Leuk Res. 2016;53:65-73.
    PubMed     Text format     Abstract available


  59. UCHIDA T, Hagihara M, Hua J, Inoue M, et al
    The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Leuk Res. 2016;53:35-38.
    PubMed     Text format     Abstract available


  60. YIN J, Zhang F, Tao H, Ma X, et al
    Corrigendum to "BCL11A expression in acute phase chronic myeloid leukemia" [Leuk. Res. 47 (2016) 88-92].
    Leuk Res. 2016 Nov 21. pii: S0145-2126(16)30165.
    PubMed     Text format    


  61. SALSON M, Giraud M, Caillault A, Grardel N, et al
    High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
    Leuk Res. 2016;53:1-7.
    PubMed     Text format     Abstract available


  62. ZHANG YH, Lu AD, Yang L, Li LD, et al
    PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
    Leuk Res. 2016;52:43-49.
    PubMed     Text format     Abstract available


  63. MOLONEY JN, Stanicka J, Cotter TG
    Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia.
    Leuk Res. 2016;52:34-42.
    PubMed     Text format     Abstract available


  64. VOJCEK A, Pajor G, Alpar D, Matics R, et al
    Conserved hierarchical gain of chromosome 4 is an independent prognostic factor in high hyperdiploid pediatric acute lymphoblastic leukemia.
    Leuk Res. 2016;52:28-33.
    PubMed     Text format     Abstract available


  65. CHAVEZ-GONZALEZ A, Centeno-Llanos S, Moreno-Lorenzana D, Sandoval-Esquivel MA, et al
    Casiopeina III-Ea, a copper-containing small molecule, inhibits the in vitro growth of primitive hematopoietic cells from chronic myeloid leukemia.
    Leuk Res. 2016;52:8-19.
    PubMed     Text format     Abstract available


    October 2016
  66. SABNIS HS, Bradley HL, Tripathi S, Yu WM, et al
    Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine.
    Leuk Res. 2016;50:132-140.
    PubMed     Text format     Abstract available


  67. CHEN J, Cheng J, Yi J, Xie B, et al
    Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
    Leuk Res. 2016;50:116-122.
    PubMed     Text format     Abstract available


    September 2016
  68. SHIMIZU R, Muto T, Aoyama K, Choi K, et al
    Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
    Leuk Res. 2016;50:85-94.
    PubMed     Text format     Abstract available


  69. KOST SE, Bouchard ED, LaBossiere E, Ye X, et al
    Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
    Leuk Res. 2016;50:63-71.
    PubMed     Text format     Abstract available


  70. LEE NH, Choi YB, Yi ES, Lee SH, et al
    Monosomal karyotype is not a predictor of dismal outcome in childhood de novo acute myeloid leukemia.
    Leuk Res. 2016;50:57-62.
    PubMed     Text format     Abstract available


  71. HONG M, Xia Y, Zhu Y, Zhao HH, et al
    TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
    Leuk Res. 2016;50:72-77.
    PubMed     Text format     Abstract available


  72. MOLICA S, Polliack A
    Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
    Leuk Res. 2016;50:31-36.
    PubMed     Text format     Abstract available


  73. KYRTSONIS MC, Maltezas D
    New evidence of gene inactivation by aberrant DNA-Methylation in T-cell leukemia, with treatment implications.
    Leuk Res. 2016;50:29-30.
    PubMed     Text format    


  74. LOU Y, Suo S, Tong H, Qian W, et al
    Hypofibrinogenemia as a clue in the presumptive diagnosis of acute promyelocytic leukemia.
    Leuk Res. 2016;50:11-16.
    PubMed     Text format     Abstract available


  75. LECLERC GM, Zheng S, Leclerc GJ, DeSalvo J, et al
    The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leuk Res. 2016;50:1-10.
    PubMed     Text format     Abstract available


  76. MIYAMURA K, Miyamoto T, Tanimoto M, Yamamoto K, et al
    Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
    Leuk Res. 2016;51:11-18.
    PubMed     Text format     Abstract available


  77. SUN Y, Shen H, Xu T, Yang Z, et al
    Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Leuk Res. 2016;49:102-107.
    PubMed     Text format     Abstract available


  78. VISANI G, Manti A, Valentini L, Canonico B, et al
    Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia.
    Leuk Res. 2016;50:50-56.
    PubMed     Text format     Abstract available


    August 2016
  79. HORVAT TZ, Pecoraro JJ, Daley RJ, Buie LW, et al
    The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Leuk Res. 2016;50:17-20.
    PubMed     Text format     Abstract available


  80. JASTANIAH W, Al Ghemlas I, Al Daama S, Ballourah W, et al
    Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Leuk Res. 2016;49:66-72.
    PubMed     Text format     Abstract available


  81. BERMAN E, Jhanwar S, Hedvat C, Arcila ME, et al
    Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS.
    Leuk Res. 2016;49:108-112.
    PubMed     Text format     Abstract available


    July 2016
  82. FARHADFAR N, Litzow MR
    New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Leuk Res. 2016;49:13-21.
    PubMed     Text format     Abstract available


  83. RAVANDI F, Gojo I, Patnaik MM, Minden MD, et al
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
    Leuk Res. 2016;48:92-100.
    PubMed     Text format     Abstract available


  84. WATTS JM, Dumitriu B, Hilden P, Kishtagari A, et al
    Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.
    Leuk Res. 2016;49:62-65.
    PubMed     Text format     Abstract available


  85. GHOBADI A, Choi J, Fiala MA, Fletcher T, et al
    Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Leuk Res. 2016;49:1-6.
    PubMed     Text format     Abstract available


  86. PRASAD V, Gale RP
    Precision medicine in acute myeloid leukemia: Hope, hype or both?
    Leuk Res. 2016;48:73-77.
    PubMed     Text format     Abstract available


  87. SHIN TH, Brynczka C, Dayyani F, Rivera MN, et al
    TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.
    Leuk Res. 2016;48:46-56.
    PubMed     Text format     Abstract available


  88. COCULOVA M, Imrichova D, Seres M, Messingerova L, et al
    The expression of P-glycoprotein in leukemia cells is associated with the upregulated expression of nestin, a class 6 filament protein.
    Leuk Res. 2016;48:32-39.
    PubMed     Text format     Abstract available


  89. HARTSOCK B, Lim MJ, Roth CG, Raptis N, et al
    ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.
    Leuk Res. 2016;48:16-19.
    PubMed     Text format     Abstract available


  90. BRECCIA M, Molica M, Colafigli G, Massaro F, et al
    Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.
    Leuk Res. 2016;48:20-25.
    PubMed     Text format     Abstract available


    June 2016
  91. MATUSZAK M, Lewandowski K, Czyz A, Kiernicka-Parulska J, et al
    The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia.
    Leuk Res. 2016;47:166-171.
    PubMed     Text format     Abstract available


  92. TIMILSHINA N, Breunis H, Tomlinson G, Brandwein J, et al
    Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?
    Leuk Res. 2016;47:142-148.
    PubMed     Text format     Abstract available


  93. GRIGNANO E, Mekinian A, Braun T, Liozon E, et al
    Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.
    Leuk Res. 2016;47:136-141.
    PubMed     Text format     Abstract available


    May 2016
  94. MUSTO P, Negrini M, De Luca L, Cuneo A, et al
    Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile: Editorial for the paper "MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion".
    Leuk Res. 2016;47:114-115.
    PubMed     Text format    


  95. SHIRAI Y, Miyashita M, Kawa M, Motokura T, et al
    Evaluation of care for leukemia and lymphoma patients during their last hospitalization from the perspective of the bereaved family.
    Leuk Res. 2016;47:93-99.
    PubMed     Text format     Abstract available


  96. CHATTERJEE R, Chattopadhyay S, Law S
    Alteration of classical and hematopoiesis specific p53 pathway in the bone marrow hematopoietic stem/progenitor compartment facilitates leukemia progression in experimental mice.
    Leuk Res. 2016;47:70-77.
    PubMed     Text format     Abstract available


  97. YIN J, Zhang F, Tao H, Ma X, et al
    BCL11A expression in acute phase chronic myeloid leukemia.
    Leuk Res. 2016;47:88-92.
    PubMed     Text format     Abstract available


  98. WANG J, Hu J, Jin Z, Wan H, et al
    The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Leuk Res. 2016;47:32-40.
    PubMed     Text format     Abstract available


  99. STOSKUS M, Eidukaite A, Griskevicius L
    Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells.
    Leuk Res. 2016;47:16-21.
    PubMed     Text format     Abstract available


  100. CHAVEZ JC, Piris-Villaespesa M, Dalia S, Powers J, et al
    Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Leuk Res. 2016;47:78-83.
    PubMed     Text format     Abstract available


  101. MEDINGER M, Heim D, Gerull S, Halter J, et al
    Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Leuk Res. 2016;47:22-25.
    PubMed     Text format     Abstract available


  102. ISHIYAMA K, Yamaguchi T, Eto T, Ohashi K, et al
    Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.
    Leuk Res. 2016;47:47-53.
    PubMed     Text format     Abstract available


  103. TANG FF, Huang XJ, Zhang XH, Chen H, et al
    Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
    Leuk Res. 2016;47:8-15.
    PubMed     Text format     Abstract available


  104. MANZONI D, Catallo R, Chebel A, Baseggio L, et al
    The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
    Leuk Res. 2016;47:1-7.
    PubMed     Text format     Abstract available


  105. MAGWOOD-GOLSTON JS, Kessler S, Bennett CL
    Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry.
    Leuk Res. 2016;44:61-4.
    PubMed     Text format     Abstract available


  106. GENG S, Yao H, Weng J, Tong J, et al
    Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
    Leuk Res. 2016;44:17-24.
    PubMed     Text format     Abstract available


    April 2016
  107. SEITER K, Ahmed N, Shaikh A, Baskind P, et al
    CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
    Leuk Res. 2016;46:74-78.
    PubMed     Text format     Abstract available


  108. FANG J, Zhang R, Wang H, Hong M, et al
    Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Leuk Res. 2016;46:61-68.
    PubMed     Text format     Abstract available


  109. MIAN YA, Zeleznik-Le NJ
    The miR-17 approximately 92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
    Leuk Res. 2016;46:51-60.
    PubMed     Text format     Abstract available


  110. VAN DE VELDE AL, Beutels P, Smits EL, Van Tendeloo VF, et al
    Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.
    Leuk Res. 2016;46:26-29.
    PubMed     Text format     Abstract available


  111. HERNANDEZ-SANCHEZ M, Rodriguez-Vicente AE, Hernandez JA, Lumbreras E, et al
    MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
    Leuk Res. 2016;46:30-36.
    PubMed     Text format     Abstract available


  112. WANG Q, Li Y, Cheng J, Chen L, et al
    Sam68 affects cell proliferation and apoptosis of human adult T-acute lymphoblastic leukemia cells via AKT/mTOR signal pathway.
    Leuk Res. 2016;46:1-9.
    PubMed     Text format     Abstract available


  113. SAINI L, Brandwein J, Turner R, Larratt L, et al
    Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
    Leuk Res. 2016;45:47-52.
    PubMed     Text format     Abstract available


  114. TANAHASHI T, Sekiguchi N, Matsuda K, Takezawa Y, et al
    Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations.
    Leuk Res. 2016;45:8-13.
    PubMed     Text format     Abstract available


  115. TIAN H, Xu Y, Liu L, Yan L, et al
    Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.
    Leuk Res. 2016;45:40-46.
    PubMed     Text format     Abstract available


  116. MIRJI G, Bhat J, Kode J, Banavali S, et al
    Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.
    Leuk Res. 2016;45:33-39.
    PubMed     Text format     Abstract available


  117. NISHIOKA C, Ikezoe T, Yang J, Yokoyama A, et al
    BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells.
    Leuk Res. 2016;45:24-32.
    PubMed     Text format     Abstract available


  118. VAUGHN JE, Buckley SA, Walter RB
    Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.
    Leuk Res. 2016;45:53-58.
    PubMed     Text format     Abstract available


  119. LI XM, Zhang LP, Wang YZ, Lu AD, et al
    CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients.
    Leuk Res. 2016;43:33-8.
    PubMed     Text format     Abstract available


    March 2016
  120. WENG XQ, Sheng Y, Ge DZ, Wu J, et al
    RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBPbeta, C/EBPepsilon and PU.1.
    Leuk Res. 2016;45:68-74.
    PubMed     Text format     Abstract available


  121. HO H, Skaist AM, Pallavajjala A, Yonescu R, et al
    NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.
    Leuk Res. 2016;45:1-7.
    PubMed     Text format     Abstract available


  122. MOLTENI A, Riva M, Borin L, Bernardi M, et al
    The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
    Leuk Res. 2016;42:21-7.
    PubMed     Text format     Abstract available


  123. CARRETT-DIAS M, Almeida LK, Pereira JL, Almeida DV, et al
    Cell differentiation and the multiple drug resistance phenotype in human erythroleukemic cells.
    Leuk Res. 2016;42:13-20.
    PubMed     Text format     Abstract available


  124. XIAO D, Shi Y, Fu C, Jia J, et al
    Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.
    Leuk Res. 2016;42:75-9.
    PubMed     Text format     Abstract available


    February 2016
  125. ZHU HH, Jiang H, Jiang Q, Jia JS, et al
    Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
    Leuk Res. 2016;44:40-44.
    PubMed     Text format     Abstract available


  126. RADIVOYEVITCH T, Sachs RK, Gale RP, Smith MR, et al
    Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia.
    Leuk Res. 2016;43:9-12.
    PubMed     Text format     Abstract available


  127. FRAISON JB, Mekinian A, Grignano E, Kahn JE, et al
    Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2016;43:13-17.
    PubMed     Text format     Abstract available


  128. PEARSON E, McGarry L, Gala S, Nieset C, et al
    Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy.
    Leuk Res. 2016;43:1-8.
    PubMed     Text format     Abstract available


  129. GRIFFITHS EA, Brady WE, Tan W, Vigil CE, et al
    A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2016;43:44-48.
    PubMed     Text format     Abstract available


  130. SULEIMAN Y, Dalia S, Liu JJ, Bowers JW, et al
    Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Res. 2016;42:52-58.
    PubMed     Text format     Abstract available


  131. BAINSCHAB A, Quehenberger F, Greinix HT, Krause R, et al
    Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
    Leuk Res. 2016;42:47-51.
    PubMed     Text format     Abstract available


  132. PULLARKAT V
    Treatment of the older adult with ALL: An urgent call to action.
    Leuk Res. 2016;41:3-4.
    PubMed     Text format    


  133. WAMPFLER J, Federzoni EA, Torbett BE, Fey MF, et al
    The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation.
    Leuk Res. 2016;41:96-102.
    PubMed     Text format     Abstract available


  134. GUPTA SK, Bakhshi S, Kumar L, Seth R, et al
    IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
    Leuk Res. 2016;41:7-11.
    PubMed     Text format     Abstract available


    January 2016
  135. CHEN H, Wang N, Yang G, Guo Y, et al
    The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.
    Leuk Res. 2016;42:28-36.
    PubMed     Text format     Abstract available


  136. MINETTO P, Guolo F, Miglino M
    Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia.
    Leuk Res. 2016 Jan 22. pii: S0145-2126(16)30005.
    PubMed     Text format    


  137. NAREN D, Wu J, Gong Y, Yan T, et al
    Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
    Leuk Res. 2016 Jan 16. pii: S0145-2126(16)30007.
    PubMed     Text format     Abstract available


  138. ACHILLE NJ, Othus M, Phelan K, Zhang S, et al
    Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
    Leuk Res. 2016 Jan 15. pii: S0145-2126(16)30004.
    PubMed     Text format     Abstract available


  139. SAROVA I, Brezinova J, Zemanova Z, Ransdorfova S, et al
    Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.
    Leuk Res. 2016 Jan 8. pii: S0145-2126(16)30001.
    PubMed     Text format     Abstract available


  140. NISCOLA P, Cupelli L, Dentamaro T, Fabritiis P, et al
    Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome?
    Leuk Res. 2016 Jan 4. pii: S0145-2126(15)30571.
    PubMed     Text format    


  141. MINAKATA D, Fujiwara SI, Ito S, Mashima K, et al
    A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Leuk Res. 2016 Jan 2. pii: S0145-2126(15)30570.
    PubMed     Text format     Abstract available


  142. LOU YJ, Pan XR, Jia PM, Jin J, et al
    RIG-G inhibits the proliferation of NB4 cells and propels ATRA-induced differentiation of APL cells.
    Leuk Res. 2016;40:83-9.
    PubMed     Text format     Abstract available


  143. VETTER T, Borowski A, Wohlmann A, Ranjan N, et al
    Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.
    Leuk Res. 2016;40:38-43.
    PubMed     Text format     Abstract available


  144. MELE G, Coppi MR, Guaragna G, Spina A, et al
    Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
    Leuk Res. 2016;40:30-2.
    PubMed     Text format     Abstract available


  145. KELLNER J, Wierda W, Shpall E, Keating M, et al
    Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL.
    Leuk Res. 2016;40:54-9.
    PubMed     Text format     Abstract available


  146. VIDRIALES MB, Perez-Lopez E, Pegenaute C, Castellanos M, et al
    Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
    Leuk Res. 2016;40:1-9.
    PubMed     Text format     Abstract available


  147. MONTANO G, Ullmark T, Jernmark-Nilsson H, Sodaro G, et al
    The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.
    Leuk Res. 2016;40:60-7.
    PubMed     Text format     Abstract available


    December 2015
  148. ITONAGA H, Iwanaga M, Aoki K, Aoki J, et al
    Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
    Leuk Res. 2015 Dec 24. pii: S0145-2126(15)30561.
    PubMed     Text format     Abstract available


  149. CHIARETTI S, Brugnoletti F, Messina M, Paoloni F, et al
    CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
    Leuk Res. 2015 Dec 23. pii: S0145-2126(15)30557.
    PubMed     Text format     Abstract available


  150. ZHOU L, Liu X, Wang X, Sun Z, et al
    CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Leuk Res. 2015 Dec 19. pii: S0145-2126(15)30560.
    PubMed     Text format     Abstract available


  151. SEITER K
    Therapy for relapsed acute lymphoblastic leukemia: Still a role for standard chemotherapy regimens?
    Leuk Res. 2015 Dec 19. pii: S0145-2126(15)30564.
    PubMed     Text format    


  152. GHASEMZADEH M, Hosseini E, Schwarer AP, Pourfathollah AA, et al
    NK cell maturation to CD56 subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2015 Dec 17. pii: S0145-2126(15)30559.
    PubMed     Text format     Abstract available


  153. ANDERSSON BS
    Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An ana
    Leuk Res. 2015 Dec 12. pii: S0145-2126(15)30554.
    PubMed     Text format    


  154. TAO H, Ma X, Su G, Yin J, et al
    BCL11A expression in acute myeloid leukemia.
    Leuk Res. 2015 Dec 7. pii: S0145-2126(15)30558.
    PubMed     Text format     Abstract available


  155. BERMAN E, Maloy M, Devlin S, Jhanwar S, et al
    Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.
    Leuk Res. 2015 Dec 2. pii: S0145-2126(15)30549.
    PubMed     Text format     Abstract available


  156. RIBERA JM, Garcia O, Oriol A, Gil C, et al
    Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.
    Leuk Res. 2015 Dec 2. pii: S0145-2126(15)30552.
    PubMed     Text format     Abstract available


  157. FAN SJ, Li HB, Cui G, Kong XL, et al
    miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia.
    Leuk Res. 2015 Dec 1. pii: S0145-2126(15)30556.
    PubMed     Text format     Abstract available


  158. ABDELHAMED S, Kurre P
    Hope and hype surrounding circulating microRNA as potential next generation AML biomarkers.
    Leuk Res. 2015;39:1309-11.
    PubMed     Text format    


  159. BADAR T, Patel KP, Thompson PA, DiNardo C, et al
    Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Leuk Res. 2015;39:1367-74.
    PubMed     Text format     Abstract available


  160. DAMDINSUREN A, Matsushita H, Ito M, Tanaka M, et al
    FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Leuk Res. 2015;39:1405-13.
    PubMed     Text format     Abstract available


  161. KOUTOVA L, Sterbova M, Pazourkova E, Pospisilova S, et al
    The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
    Leuk Res. 2015;39:1389-95.
    PubMed     Text format     Abstract available


    November 2015
  162. LANDFELDT E, Eriksson J, Ireland S, Musingarimi P, et al
    Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
    Leuk Res. 2015 Nov 12. pii: S0145-2126(15)30546.
    PubMed     Text format     Abstract available


    October 2015
  163. LIU N, Ning HM, Hu LD, Jiang M, et al
    Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Leuk Res. 2015 Oct 19. pii: S0145-2126(15)30533.
    PubMed     Text format     Abstract available


  164. GANSTER C, Shirneshan K, Salinas-Riester G, Braulke F, et al
    Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
    Leuk Res. 2015;39:1079-87.
    PubMed     Text format     Abstract available


  165. WANG WZ, Pu QH, Lin XH, Liu MY, et al
    Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
    Leuk Res. 2015;39:1117-24.
    PubMed     Text format     Abstract available


  166. PARK SH, Park CJ, Kim DY, Lee BR, et al
    MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation.
    Leuk Res. 2015;39:1109-16.
    PubMed     Text format     Abstract available


  167. MAKSIMOVIC-IVANIC D, Mojic M, Bulatovic M, Radojkovic M, et al
    The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
    Leuk Res. 2015;39:1088-95.
    PubMed     Text format     Abstract available


    September 2015
  168. PARK BG, Park CJ, Jang S, Chi HS, et al
    Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Leuk Res. 2015 Sep 10. pii: S0145-2126(15)30381.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: